Keywords: Clavis Pharma, Clovis Oncology, CP-4126
Clavis Pharma and Clovis Oncology sign $380 million deal for anti-cancer agent CP-4126
Article | 26 November 2009
Norwegian oncology focussed Clavis Pharma and USA-based Clovis Oncology, the newly-formed oncology company led by former Pharmion Corp executives, have ...
Enjoying this article? To continue reading you need to login or subscribe.
Subscribe now
for unlimited access to all articles
Subscriptions are £60 per month, pay as you go.
Find out more details.
Already a subscriber? Click here to log in
- Drug prices to plunge as Indian government announces plans to regulate rates of 652 medicines
- Elan makes "transformational" acquisitions and a divestment
- HIV vaccines: small biotech and government-funded organizations will step in where Big Pharma has fallen short, says analyst
- CIS countries prepare for the introduction of drug reimbursement schemes
- Greek research-based drugmaker group AIFD challenges generics assumptions in Draft Patent Law
